Pandemic Influenza Vaccine H5n1 Astrazeneca

A/Vietnam/1203/2004 (H5N1), the active ingredient in Pandemic Influenza Vaccine H5N1 Astrazeneca, is a vaccine presented as a sterile intranasal preparation for intranasal use. It is intended to stimulate immunity against pandemic influenza caused by the H5N1 virus in adults and at‑risk populations.

GNH USA supplies Pandemic Influenza Vaccine H5N1 Astrazeneca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, ensuring timely delivery and cold‑chain integrity.

Pandemic Influenza Vaccine H5N1 Astrazeneca is an influenza vaccine used to prevent infection by the H5N1 virus. - Pandemic H5N1 influenza: provides immunization to reduce risk of infection in adults and high‑risk groups. - Avian influenza exposure: induces protective immunity for individuals with occupational or travel exposure to H5N1‑affected regions. - Pandemic preparedness programs: contributes to national stockpiles aimed at mitigating potential H5N1 outbreaks.

Common and serious adverse reactions have been reported following intranasal administration of the vaccine.